Skip to main content
Top
Published in: AIDS Research and Therapy 1/2022

Open Access 01-12-2022 | Human Immunodeficiency Virus | Research

Determinants and reasons for switching anti-retroviral regimen among HIV-infected youth in a large township of South Africa (2002–2019)

Authors: Anita Kabarambi, Sheila Balinda, Andrew Abaasa, Dolphina Cogill, Catherine Orrell

Published in: AIDS Research and Therapy | Issue 1/2022

Login to get access

Abstract

Background

There are limited data exploring antiretroviral therapy (ART) changes and time to change among South Africa young people living with HIV/AIDS.

Objective

We describe the time to first drug switch, which includes ART regimen change (three drug switch) and substitutions (single drug switch). We describe common reasons for ART switch among young people aged 10 to 24 years in South Africa.

Methods

We conducted a retrospective cohort study at a primary health care clinic in Cape Town, South Africa, providing ART to HIV-infected adolescents and adults since 2002. Those aged 10 to 24 years at ART initiation, who accessed care clinic between September 2002 and April 2019. Data was retrieved from electronic information systems: ART regimens, ART changes, dates for initiation or stop of each drug/regimen, laboratory results (viral loads, haemoglobin, liver enzyme results, and creatinine to support the reason for ART switch. From written records, we abstracted reason for single drug switch or regimen change, as well as socio demographic and clinical data. We fitted cox regression models to determine factors associated with ART switch (Having a change in one or more drugs in ART combination) and the rate of occurrence.

Results

Of 2601 adolescents included, 605 (24.9%) adolescents switched ART over 5090.5 person years at risk (PYAR), a rate of 11.9 /100PYAR. Median follow-up time was 4.4 (± 3.2) years. At multivariable analysis, the older age group was protective of the risk of ART switch: adjusted Hazard Ratio [aHR] 0.78, 95% CI 0.62–0.98, transfer status [transferred out 1.42 [1.11–1.82]. The hazard of ART switch increased with more severe HIV-disease at ART start, as observed by increasing WHO clinical stage or reduced CD4 count at baseline. The primary reasons for ART switch were side effects (20.0%), virological failure (17.9%) and formulation switch (27.8%). Others reasons included pregnancy, Hepatitis B, tuberculosis and psychosis.

Conclusion

ART switches are frequent and occur at a consistent rate across 7.5 years from initiation. The main reasons for ART switch were virological failure and drug side effects.
Literature
1.
go back to reference UNICEF. HIV and AIDS in adolescents. 2020 (Accessed 15 March 2021). UNICEF. HIV and AIDS in adolescents. 2020 (Accessed 15 March 2021).
4.
go back to reference Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Genva: World Health Organization; 2016. Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Genva: World Health Organization; 2016.
5.
go back to reference Kanters S, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. The lancet HIV. 2017;4(10):e433–41.CrossRef Kanters S, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. The lancet HIV. 2017;4(10):e433–41.CrossRef
6.
go back to reference Stockdale AJ, et al. Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(12):1846–57.CrossRef Stockdale AJ, et al. Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor–based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(12):1846–57.CrossRef
7.
go back to reference Njuguna C, et al. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS ONE. 2013;8(5):e63596.CrossRef Njuguna C, et al. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS ONE. 2013;8(5):e63596.CrossRef
9.
go back to reference Danil LR. Queerphobic immunopolitics in the case of HIV/AIDS: political economy, the dark legacy of british colonialism, and queerphobia in Sub-Saharan Africa. Sexual Culture. 2020;25:1–19. Danil LR. Queerphobic immunopolitics in the case of HIV/AIDS: political economy, the dark legacy of british colonialism, and queerphobia in Sub-Saharan Africa. Sexual Culture. 2020;25:1–19.
10.
go back to reference Whiteley L, et al. A mobile gaming intervention to increase adherence to antiretroviral treatment for youth living with HIV: development guided by the information, motivation, and behavioral skills model. JMIR Mhealth Uhealth. 2018;6(4):e8155.CrossRef Whiteley L, et al. A mobile gaming intervention to increase adherence to antiretroviral treatment for youth living with HIV: development guided by the information, motivation, and behavioral skills model. JMIR Mhealth Uhealth. 2018;6(4):e8155.CrossRef
11.
go back to reference Hart E, et al. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients. HIV Med. 2007;8(3):186–91.CrossRef Hart E, et al. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients. HIV Med. 2007;8(3):186–91.CrossRef
12.
go back to reference Cicconi P, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11(2):104–13.CrossRef Cicconi P, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11(2):104–13.CrossRef
13.
go back to reference Keiser O, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23(14):1867.CrossRef Keiser O, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23(14):1867.CrossRef
14.
go back to reference Ammon N, Mason S, Corkery J. Factors impacting antiretroviral therapy adherence among human immunodeficiency virus–positive adolescents in Sub-Saharan Africa: a systematic review. Public Health. 2018;157:20–31.CrossRef Ammon N, Mason S, Corkery J. Factors impacting antiretroviral therapy adherence among human immunodeficiency virus–positive adolescents in Sub-Saharan Africa: a systematic review. Public Health. 2018;157:20–31.CrossRef
15.
go back to reference Merzel C, VanDevanter N, Irvine M. Adherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contexts. AIDS Patient Care STDS. 2008;22(12):977–87.CrossRef Merzel C, VanDevanter N, Irvine M. Adherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contexts. AIDS Patient Care STDS. 2008;22(12):977–87.CrossRef
16.
go back to reference Kim MH, et al. High self-reported non-adherence to antiretroviral therapy amongst adolescents living with HIV in Malawi: barriers and associated factors. J Int AIDS Soc. 2017;20(1):21437.CrossRef Kim MH, et al. High self-reported non-adherence to antiretroviral therapy amongst adolescents living with HIV in Malawi: barriers and associated factors. J Int AIDS Soc. 2017;20(1):21437.CrossRef
17.
go back to reference Kazooba P, et al. Virological failure on first-line antiretroviral therapy; associated factors and a pragmatic approach for switching to second line therapy–evidence from a prospective cohort study in rural South-Western Uganda, 2004–2011. Pan African Med J. 2018;29(1):1–16. Kazooba P, et al. Virological failure on first-line antiretroviral therapy; associated factors and a pragmatic approach for switching to second line therapy–evidence from a prospective cohort study in rural South-Western Uganda, 2004–2011. Pan African Med J. 2018;29(1):1–16.
Metadata
Title
Determinants and reasons for switching anti-retroviral regimen among HIV-infected youth in a large township of South Africa (2002–2019)
Authors
Anita Kabarambi
Sheila Balinda
Andrew Abaasa
Dolphina Cogill
Catherine Orrell
Publication date
01-12-2022
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2022
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-022-00453-4

Other articles of this Issue 1/2022

AIDS Research and Therapy 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine